查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2014753

人類肝臟模型市場：按模型類型、細胞來源、應用和最終用戶分類－2026-2032年全球市場預測

Human Liver Model Market by Model Type, Cell Source, Application, End Users - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年人類肝臟模型市場價值為 16.6 億美元，預計到 2026 年將成長至 17.8 億美元，複合年成長率為 9.00%，到 2032 年將達到 30.5 億美元。

主要市場統計數據
基準年 2025 16.6億美元
預計年份：2026年 17.8億美元
預測年份 2032 30.5億美元
複合年成長率 (%) 9.00%

全面概述了技術整合和實踐檢驗如何影響人類肝臟模型的未來效用和實用化。

人類肝臟模型的演進代表了生物學、工程學和計算科學的融合，重塑了產業界和學術界進行肝臟相關研發的方式。支架設計、微生理系統、幹細胞分化方案和多組體學分析等方面的進步，共同提高了模型的生理有效性，並實現了對藥物代謝、肝毒性和疾病建模更具預測性的分析。這些技術進步正被應用於從早期標靶檢驗到後期轉化研究的各個工作流程中，迫使各機構重新思考實驗設計和資源分配。

突破性的工程技術、以品質為中心的商業化以及共享標準如何重塑先進人類肝臟模型的接受度和應用案例。

人類肝臟模型領域正經歷一場變革，這得益於科學突破和相關人員不斷變化的期望。細胞製備技術的進步、微流體技術的整合以及精密的測量結果，正將微生理系統和肝臟類器官從小眾研究工具轉變為能夠為藥物研發和安全性評估提供決策依據的平台。這種轉變促進了跨學科合作，將組織工程與電腦預測相結合，從而建立更豐富、更多模態的資料集，以支持機制的闡明。

本分析探討了到 2025 年關稅趨勢的變化將如何鼓勵模型開發商實現策略供應鏈多元化、在地化生產和提高採購韌性。

2025年的關稅政策和貿易趨勢為那些從國際採購材料、設備和模型系統的機構帶來了一系列新的策略考量。為了應對這些關稅帶來的成本壓力，許多供應商和終端用戶正在重新評估其供應鏈佈局和籌資策略，以維持其科學研究活動的連續性。這加速了人們對區域製造能力的關注，這些能力用於生產微流體晶片、細胞外基質材料以及支援可重複肝臟模型生產的標準化耗材等關鍵組件。

細分市場層面的洞察揭示了型號類型、電池來源、應用重點和最終用戶優先級如何決定部署路徑和商業化策略。

對模型細分的詳細分析揭示了每種模型類型、細胞來源、應用和最終用戶類別的不同引入因素和操作要求。模型類型涵蓋了從傳統的2D模型到新興的3D模型、離體構建體、電腦模擬和肝臟類器官，每種模型在生理有效性、可擴展性和整合複雜性之間都存在獨特的權衡。優先考慮高通量篩檢的機構通常會保留2D平台，因為它們具有成本效益和簡便性；而強調轉化保真度的項目則正在增加對3D構建體和類器官的投資，以捕獲多細胞結構和功能指標。

美洲、歐洲、中東和非洲以及亞太地區的戰略差異和能力將決定採用軌跡和合作機會。

區域趨勢對美洲、歐洲、中東和非洲以及亞太地區的部署計畫、商業化策略和夥伴關係模式產生了重大影響。在美洲，強大的轉化醫學生態系統以及接近性主要製藥中心的地理優勢，促進了高保真3D系統和類器官的早期應用，特別注重將模型整合到安全性和代謝工作流程中。該地區的資金籌措環境和創投活動也為那些能夠證明符合監管要求並具備可擴展生產能力的Start-Ups提供了支持。

深入了解競爭定位、合作模式和檢驗主導的差異化策略，這些策略將塑造人類肝臟模型領域的領導潛力。

成熟企業、專業Start-Ups和服務供應商之間的競爭格局，取決於它們在平台工程、細胞來源、檢測方法開發和法規遵循方面的互補優勢。領先的學術衍生公司和生物技術公司通常透過專有的差異化方案、微加工技術以及整合的分析工具鏈來脫穎而出，從而為終端用戶提供更可靠的測量結果。同時，受託研究機構(CRO) 和平台提供者正日益建立戰略合作夥伴關係，以提供滿足端到端需求的捆綁式服務，涵蓋從模型合格和檢測檢驗到符合良好實驗室規範 (GLP) 的數據收集等各個環節。

為領導者制定可操作且優先的行動方案，以規範檢驗、擴大生產規模、建立策略合作夥伴關係，並使經營模式與最終用戶需求保持一致。

產業領導者應採取前瞻性策略，平衡科學嚴謹性、營運擴充性和商業性可行性。首先，應優先考慮建立標準化的驗證框架，將模型輸出與臨床相關的生物標記進行映射，從而為藥物研發和安全性工作流程的整合建立更清晰的決策標準。同時，應投資於可擴展的生產和品質體系，以降低變異性，並縮短合作夥伴和客戶的合格週期。儘早與監管相關人員接洽，並參與跨行業的標竿學習舉措，將有助於加速市場接受度，並降低轉換風險。

採用嚴謹的混合方法，結合與專家的初步訪談、技術文獻的整合和迭代檢驗，確保獲得實用可靠的見解。

本執行摘要的研究結合了對各領域專家的結構化一手訪談，以及對同行評審文獻、技術白皮書、監管指南和企業資訊披露的二次整合。關鍵的定性輸入包括對平台開發人員、細胞採購專家、製藥和合約研究環境中的最終用戶以及在疾病相關領域應用模型的轉化科學家的訪談。這些對話深入剖析了營運挑戰、檢驗重點以及商業性化應用的促進因素。

重點強調營運準備、嚴格檢驗和策略一致性，這是主導模型進步轉化為實際研究和商業性價值的關鍵因素。

總之，在技術融合、細胞獲取方式改進以及對可重複性和監管相關性的日益成長的期望的推動下，人類肝臟模型生態系統正從探索性創新走向成熟應用。投資於穩健驗證、可擴展生產和策略夥伴關係的相關人員將更有利於把模型性能轉化為具體的科學研究和商業性成果。同時，地緣政治因素和關稅考量正在重塑供應鏈策略，凸顯了本地能力建構和採購多元化的必要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：按模型類型分類的人類肝臟模型市場

  • 2D模型
  • 3D模型
  • 體外模型
  • In Silico模型
  • 肝臟類器官

第9章：以細胞來源分類的人類肝臟模型市場

  • 永生化肝細胞株
  • 人類原代肝細胞
  • 幹細胞衍生模型

第10章：人類肝臟模型市場：依應用分類

  • 藥物發現
  • 教育
    • 生理學研究
    • 毒理學研究

第11章：人類肝臟模型市場：以最終用戶分類

  • 生技公司
  • 合約研究機構
  • 製藥公司
  • 研究機構

第12章：人類肝臟模型市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：人類肝臟模型市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：人類肝臟模型市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國人類肝臟模型市場

第16章：中國人體肝臟模型市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Ascendance Bio
  • BioIVT LLC
  • Cellink Global by BICO Group AB
  • CN Bio Innovations Ltd.
  • Corning Incorporated
  • Cyfuse Biomedical KK
  • EISCO Scientific LLC
  • Emulate Inc.
  • Hurel Corporation
  • InSphero AG
  • Kirkstall Ltd
  • MIMETAS BV
  • NeurOmics, Inc.
  • Organovo Holdings Inc.
  • Pandorum Technologies Private Limited
  • PhoenixBio Co., Ltd.
  • STEMCELL Technologies Inc.
Product Code: MRR-43127F7278DC

The Human Liver Model Market was valued at USD 1.66 billion in 2025 and is projected to grow to USD 1.78 billion in 2026, with a CAGR of 9.00%, reaching USD 3.05 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.66 billion
Estimated Year [2026] USD 1.78 billion
Forecast Year [2032] USD 3.05 billion
CAGR (%) 9.00%

A panoramic overview of technological integration and practical validation shaping the future utility and operational adoption of human liver models

The evolution of human liver models represents a convergence of biology, engineering, and computational sciences that is reshaping how industry and academia approach liver-focused research and development. Advances in scaffold design, microphysiological systems, stem cell differentiation protocols, and multi-omics readouts have collectively improved physiological relevance, enabling more predictive interrogation of drug metabolism, hepatotoxicity, and disease modeling. These technological improvements are being adopted across diverse workflows, from early-stage target validation to later-stage translational research, which is prompting institutions to reassess experimental design and resource allocation.

Importantly, the pandemic-era acceleration of remote collaboration and digital data integration has amplified demand for in silico approaches that complement wet-lab models, thereby creating hybrid workflows that combine 2D platforms and 3D constructs with computational simulations. As a result, stakeholders are placing greater emphasis on model reproducibility, standardization, and compatibility with high-content readouts. Consequently, organizations that prioritize cross-disciplinary validation and scalable manufacturing practices will be better positioned to translate model improvements into reproducible, regulatory-relevant outcomes.

Looking ahead, the narrative is shifting from proof-of-concept demonstrations to operationalization and qualification of human liver models for routine use. This transition demands strategic investments in quality management, assay harmonization, and transparent benchmarking against clinical and preclinical endpoints, establishing a foundation for broader utility in drug safety, disease research, and education.

How breakthrough engineering, quality-driven commercialization, and collaborative standards are reconfiguring acceptance and use cases for advanced human liver models

The landscape for human liver models is undergoing transformative shifts driven by a combination of scientific breakthroughs and changing stakeholder expectations. Microphysiological systems and liver organoids are moving from niche research tools to platforms that can inform decision-making across drug discovery and safety assessment, driven by improvements in cellular sourcing, microfluidic integration, and readout sophistication. This shift is encouraging multidisciplinary partnerships that marry tissue engineering with computational prediction, thereby enabling richer, multi-modal datasets that support mechanistic insights.

Simultaneously, end users are demanding higher standards for reproducibility and throughput, prompting innovations in manufacturing, automation, and quality control. Contract research organizations and biotech companies are increasingly offering turnkey model solutions, lowering barriers to adoption for pharmaceutical programs and academic labs that need robust, scalable options. In parallel, academic groups continue to push the envelope on disease-specific modeling, particularly for metabolic and fibrotic liver conditions, which is expanding the biological contexts in which liver models are considered indispensable.

These developments are also prompting new modalities of collaboration across sectors, including pilot qualification studies with regulators, pre-competitive consortia to define benchmarking standards, and private-public partnerships that accelerate translational pathways. Collectively, these shifts are redefining expectations for what constitutes a validated, decision-grade liver model.

Analyzing how evolving tariff dynamics in 2025 are prompting strategic supply chain diversification, localized manufacturing, and procurement resilience for model developers

Tariff policies and trade dynamics in 2025 have introduced a new set of strategic considerations for organizations that source materials, equipment, and model systems internationally. In response to these tariff-induced cost pressures, many suppliers and end users are reevaluating supply chain footprints and sourcing strategies to maintain continuity of scientific operations. This has accelerated interest in regional manufacturing capabilities for critical components such as microfluidic chips, extracellular matrix materials, and standardized consumables that support reproducible liver model production.

As a result, stakeholders are increasingly prioritizing supply chain resilience through diversification of vendors and closer supplier relationships that offer greater transparency and contingency planning. At the same time, organizations are assessing the cost-benefit of vertically integrating certain capabilities-such as cell derivation, quality control, and assay automation-versus relying on external service providers. These strategic moves are being balanced with the need to preserve access to specialized expertise and innovation hubs that remain geographically concentrated.

Consequently, the tariff environment has catalyzed a broader rethinking of procurement, manufacturing scale, and partnership models, underlining the importance of adaptive sourcing strategies, localized production investments, and contractual mechanisms that mitigate geopolitical and regulatory risk.

Segment-level intelligence revealing how model type, cell source, application focus, and end-user priorities determine adoption pathways and commercialization strategies

A nuanced view of segmentation reveals differentiated adoption drivers and operational imperatives across model type, cell source, application, and end-user categories. Model types span traditional 2D models and emerging 3D models, Ex Vivo constructs, In Silico simulations, and Liver Organoids, each offering unique trade-offs between physiological relevance, scalability, and integration complexity. Organizations that prioritize high-throughput screening often retain 2D platforms for their cost-effectiveness and simplicity, while programs focused on translational fidelity are increasingly investing in 3D constructs and organoids to capture multicellular architecture and functional metrics.

Cell source decisions-ranging from Immortalized Liver Cell Lines and Primary Human Hepatocytes to Stem Cell-Derived Models-inform both experimental design and downstream interpretation. Primary cells offer clinically proximal phenotypes but present supply and variability challenges, whereas stem cell-derived approaches provide scalability and disease modeling flexibility. Immortalized lines maintain utility for mechanistic probing and assay development, especially when combined with genetic editing and standardized readouts. These choices cascade into application-specific strategies: drug discovery initiatives balance throughput and predictive value, while educational uses, including physiological and toxicology studies, emphasize reproducibility and cost-efficiency to support curriculum and training objectives.

End-user profiles further shape technology adoption pathways, with Biotech Companies and Pharmaceutical Companies focusing on translational validation and integration with preclinical pipelines, Contract Research Organizations centering on service scalability and regulatory alignment, and Research Laboratories prioritizing experimental flexibility and novel hypothesis testing. Understanding how model type, cell source, application, and end-user priorities interrelate is critical for designing commercialization approaches, partnerships, and validation studies that meet diverse stakeholder needs.

Regional strategic contrasts and capabilities across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine adoption trajectories and partnership opportunities

Regional dynamics materially influence adoption timelines, commercialization strategies, and partnership models across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, strong translational ecosystems and proximity to major pharmaceutical hubs support early adoption of higher-fidelity 3D systems and organoids, with an emphasis on integrating models into safety and metabolism workflows. Funding landscapes and venture activity in this region also favor startups that can demonstrate regulatory alignment and scalable manufacturing.

Europe, Middle East & Africa exhibit a diverse mosaic of academic excellence, regulatory engagement, and industrial collaboration that fosters rigorous validation efforts and pre-competitive consortia. This region often leads in establishing interdisciplinary standards and ethical frameworks for complex tissue models, which in turn informs qualification pathways. In contrast, the Asia-Pacific region is notable for rapid manufacturing scale-up, cost-competitive service provision, and strategic public investment in biotechnology infrastructure, making it a pivotal zone for localized production, large-scale contract services, and clinical translation initiatives.

A regionally attuned strategy that recognizes differences in regulatory dialogue, funding mechanisms, and manufacturing capacities will be essential. Partners and investors should align operational plans with regional strengths, leveraging local talent pools and infrastructure while ensuring harmonization with global validation and quality expectations.

Insight into competitive positioning, partnership models, and validation-driven differentiation strategies that dictate leadership potential in the human liver model landscape

Competitive dynamics among established firms, specialized startups, and service providers are shaped by complementary strengths in platform engineering, cell sourcing, assay development, and regulatory engagement. Leading academic spinouts and biotech companies often differentiate through proprietary differentiation protocols, microfabrication expertise, and integrated analytical toolchains that provide end users with higher-confidence readouts. At the same time, contract research organizations and platform providers are increasingly forming strategic partnerships to offer bundled services that address end-to-end needs-from model qualification and assay validation to GLP-compatible data capture.

Collaboration between platform developers and pharmaceutical teams is becoming more frequent, with co-development agreements and pilot qualification studies used to de-risk integration into drug development pipelines. Additionally, there is growing interest in licensing arrangements and strategic investments that accelerate scale-up and market reach, especially when combined with shared validation datasets that demonstrate translational concordance. For companies seeking to compete, success depends on clear value articulation, validated performance claims, and demonstrable operational scalability to support diverse customer workflows.

Investors and corporate development teams should track partnerships, technology transfer agreements, and platform interoperability initiatives closely, as these activities often presage broader commercial uptake and create differentiation barriers based on data ecosystems and validated endpoints.

Practical, prioritized actions for leaders to standardize validation, scale manufacturing, form strategic alliances, and align commercial models with end-user needs

Industry leaders should adopt a proactive approach that balances scientific rigor, operational scalability, and commercial alignment. First, prioritize standardized validation frameworks that map model outputs to clinically relevant biomarkers, enabling clearer decision gates for integration into drug discovery and safety workflows. Concurrently, invest in scalable manufacturing and quality systems to reduce variability and shorten qualification timelines for partners and customers. Early engagement with regulatory stakeholders and participation in cross-sector benchmarking initiatives will accelerate acceptance and reduce translational risk.

Second, pursue strategic partnerships that complement internal capabilities-such as collaborations with computational biology groups for in silico integration, alliances with cell therapy innovators for enhanced cell sourcing, and service partnerships with contract research providers to expand reach. Third, tailor go-to-market strategies to end-user needs by offering flexible commercial models that include subscription-based access, pilot qualification packages, and educational licensing for academic programs. Finally, maintain an adaptive sourcing strategy to navigate geopolitical and tariff pressures by exploring regional manufacturing, multi-supplier agreements, and inventory hedging that preserve operational continuity.

By executing on these fronts, organizations can accelerate model qualification, broaden market access, and establish defensible positions grounded in validated performance and customer-centric delivery.

A rigorous mixed-methods approach combining primary expert interviews, technical literature synthesis, and iterative validation to ensure actionable and credible findings

The research underpinning this executive summary combined structured primary engagement with subject-matter experts and secondary synthesis of peer-reviewed literature, technical whitepapers, regulatory guidance, and company disclosures. Key qualitative inputs included interviews with platform developers, cell sourcing specialists, end users in pharmaceutical and contract research settings, and translational scientists who apply models in disease-relevant contexts. These conversations provided granular insights into operational challenges, validation priorities, and commercial adoption drivers.

Secondary analysis involved systematic review of methodological advancements in tissue engineering, stem cell differentiation protocols, microfluidics, and computational modeling, supplemented by examination of recent preclinical and translational studies that benchmark model performance. Data triangulation was used to cross-validate thematic findings across sources, and findings were iteratively refined through expert validation sessions to ensure technical accuracy and practical relevance. Ethical considerations, manufacturing constraints, and regulatory dialogue were also incorporated to present a balanced view that supports strategic decision-making.

This mixed-methods approach ensures that conclusions reflect both the current state of scientific advancement and the operational realities facing developers, end users, and investors.

Key takeaways emphasizing operational readiness, validation rigor, and strategic alignment that will determine who leads in translating model advancements into practical research and commercial value

In conclusion, the human liver model ecosystem is maturing from exploratory innovation toward operational readiness, driven by technological convergence, improved cellular sourcing, and higher expectations for reproducibility and regulatory relevance. Stakeholders who invest in robust validation, scalable manufacturing, and strategic partnerships will be best positioned to translate model performance into tangible research and commercial outcomes. At the same time, geopolitical and tariff considerations are reshaping supply chain strategies, highlighting the need for localized capabilities and diversified sourcing.

The implications for industry participants are clear: prioritize interoperability between wet-lab and in silico approaches, engage proactively with regulators and consortia to define acceptance criteria, and design commercial offerings that map to end-user workflows. By doing so, organizations can not only improve experimental predictability but also unlock new applications in drug discovery, toxicology education, and disease modeling that together advance both science and commercial value.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Human Liver Model Market, by Model Type

  • 8.1. 2D Models
  • 8.2. 3D Models
  • 8.3. Ex Vivo Models
  • 8.4. In Silico Models
  • 8.5. Liver Organoids

9. Human Liver Model Market, by Cell Source

  • 9.1. Immortalized Liver Cell Lines
  • 9.2. Primary Human Hepatocytes
  • 9.3. Stem Cell-Derived Models

10. Human Liver Model Market, by Application

  • 10.1. Drug Discovery
  • 10.2. Education
    • 10.2.1. Physiological Studies
    • 10.2.2. Toxicology Studies

11. Human Liver Model Market, by End Users

  • 11.1. Biotech Companies
  • 11.2. Contract Research Organizations
  • 11.3. Pharmaceutical Companies
  • 11.4. Research Laboratories

12. Human Liver Model Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Human Liver Model Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Human Liver Model Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Human Liver Model Market

16. China Human Liver Model Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Ascendance Bio
  • 17.6. BioIVT LLC
  • 17.7. Cellink Global by BICO Group AB
  • 17.8. CN Bio Innovations Ltd.
  • 17.9. Corning Incorporated
  • 17.10. Cyfuse Biomedical K.K.
  • 17.11. EISCO Scientific LLC
  • 17.12. Emulate Inc.
  • 17.13. Hurel Corporation
  • 17.14. InSphero AG
  • 17.15. Kirkstall Ltd
  • 17.16. MIMETAS B.V.
  • 17.17. NeurOmics, Inc.
  • 17.18. Organovo Holdings Inc.
  • 17.19. Pandorum Technologies Private Limited
  • 17.20. PhoenixBio Co., Ltd.
  • 17.21. STEMCELL Technologies Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HUMAN LIVER MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HUMAN LIVER MODEL MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL HUMAN LIVER MODEL MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA HUMAN LIVER MODEL MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HUMAN LIVER MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY 2D MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY 2D MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY 2D MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY 3D MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY 3D MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY 3D MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY EX VIVO MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY EX VIVO MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY EX VIVO MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY IN SILICO MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY IN SILICO MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY IN SILICO MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY LIVER ORGANOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY LIVER ORGANOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY LIVER ORGANOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY IMMORTALIZED LIVER CELL LINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY IMMORTALIZED LIVER CELL LINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY IMMORTALIZED LIVER CELL LINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY PRIMARY HUMAN HEPATOCYTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY PRIMARY HUMAN HEPATOCYTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY PRIMARY HUMAN HEPATOCYTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY STEM CELL-DERIVED MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY STEM CELL-DERIVED MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY STEM CELL-DERIVED MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY PHYSIOLOGICAL STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY PHYSIOLOGICAL STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY PHYSIOLOGICAL STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY TOXICOLOGY STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY TOXICOLOGY STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY TOXICOLOGY STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY BIOTECH COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY BIOTECH COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY BIOTECH COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS HUMAN LIVER MODEL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA HUMAN LIVER MODEL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 111. GCC HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GCC HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. GCC HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 114. GCC HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. GCC HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2032 (USD MILLION)
  • TABLE 116. GCC HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPEAN UNION HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPEAN UNION HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. BRICS HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 129. G7 HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. G7 HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. G7 HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 132. G7 HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. G7 HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2032 (USD MILLION)
  • TABLE 134. G7 HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 135. NATO HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. NATO HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. NATO HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 138. NATO HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. NATO HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2032 (USD MILLION)
  • TABLE 140. NATO HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 145. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2032 (USD MILLION)
  • TABLE 147. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 148. CHINA HUMAN LIVER MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. CHINA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. CHINA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 151. CHINA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. CHINA HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2032 (USD MILLION)
  • TABLE 153. CHINA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)